GENE ONLINE|News &
Opinion
Blog

2021-08-16| ChinaSpecial

Innovent Announces Gastric Cancer Trial Win for Tyvyt, Reveals Plans for Another China Approval

by Rajaneesh K. Gopinath
Share To
Earlier today, Innovent announced positive outcomes from a gastric cancer trial that evaluated Tyvyt (sintilimab injection) in combination with chemotherapy. Interim analysis shows that the combo therapy met the primary endpoint of overall survival in patients.

Approved originally for treating relapsed or refractory classical Hodgkin’s lymphoma in China, Tyvyt had recently bagged its third NMPA approval. The immunotherapy, a fully human IgG4 anti-PD-1 monoclonal antibody, was developed by Innovent in collaboration with Eli Lilly.

GO Prime with only $1.49 now

LATEST
Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
2023-03-28
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
2023-03-28
Vertex and CRISPR Collaborate Again with $330 Million Diabetes Gene Editing Deal
2023-03-28
Amway Applauded by Frost & Sullivan for Capitalizing on Innovative Competitive Strategies to Drive Differentiation in Its Home Water Treatment Solution in APAC
2023-03-28
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
2023-03-27
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Scroll to Top